OMPI – Pesquisa nas coleções internacionais e nacionais de patentes

1.WO/2021/211792TREATMENT OF CORONAVIRUS INFECTIONS WITH AURANOFIN

WO - 21.10.2021

CIP A61K 31/7135 № do pedido PCT/US2021/027404 Requerente GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor KUMAR, Mukesh

The present disclosure provides methods for treating viral infections, in particular treating coronavirus infections in a subject with auranofin.

2.20230285454PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COVID-19 COMPRISING NANO-SIZED GRAPHENE OXIDE COMPOSITE AND METHOD USING SAME

US - 14.09.2023

CIP A61K 33/44 № do pedido 18013858 Requerente BIOGO CO., LTD. Inventor Kyung Su KANG

Provided are a pharmaceutical composition for preventing or treating a coronavirus infection or infectious disease, a composition for disinfection, and a health functional food or feed composition, all including nano-sized graphene oxide, and a method of using the same. Since the nano-sized graphene oxide or a complex thereof has anti-coronavirus activity, the graphene oxide may be used for prevention or treatment of a coronavirus infection, or disinfection of coronaviruses.

3.WO/2023/073086IRON OXIDE NANOPARTICLES WITH ANTIVIRAL ACTIVITY AGAINST SARS AND MERS CORONAVIRUS

WO - 04.05.2023

CIP A61K 9/51 № do pedido PCT/EP2022/080053 Requerente CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS Inventor BARBER CASTAÑO, Domingo F.

Coronaviridae viruses usually cause mild respiratory disease in humans, nevertheless a new infectious disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019, resulting in the ongoing 2019 2021 coronavirus pandemic. The present invention discloses the use of coated iron oxide nanoparticles (IONPs) for use in the treatment and/or prevention of viral infections caused by Coronaviridae, especially those caused by respiratory syndrome-related coronaviruses such as SARS-CoV, SARS-CoV-2 and MERS-CoV. The iron oxide nanoparticles are coated with biocompatible molecules and polymers which bind to the nanoparticle core via oxygen, nitrogen and sulfur donor atoms (e.g. dextran, (3- aminopropyl)triethoxysilane or dimercaptosuccinic acid, respectively). The IONPs were found stable, non-cytotoxic in vitro and can efficiently impair virus replication, transcription and production of infectious virus. Furthermore, the IONPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.

4.WO/2023/073091IRON OXYHYDROXIDE NANOPARTICLES WITH ANTIVIRAL ACTIVITY AGAINST SARS AND MERS CORONAVIRUS

WO - 04.05.2023

CIP A61K 33/26 № do pedido PCT/EP2022/080059 Requerente CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS Inventor BARBER CASTAÑO, Domingo F.

Coronaviridae viruses usually cause mild respiratory disease in humans, nevertheless, a new infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019, resulting in the ongoing 2019-2021 coronavirus pandemic. The present invention discloses the use of coated iron oxyhydroxide nanoparticles (lOHNPs) for use in the treatment and/or prevention of viral infections caused by Coronaviridae, especially those caused by respiratory syndrome-related coronaviruses such as SARS-CoV and SARS-CoV-2 and MERS-CoV. The iron oxyhydroxide nanoparticles are coated with biocompatible molecules and polymers which bind to the nanoparticle core via oxygen (e.g. sorbitol and sucrose). The lOHNPs were found stable, non-cytotoxic in vitro and can efficiently impair virus replication and transcription. Furthermore, the lOHNPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.

5.WO/2023/079466TREATMENT OF SEQUELAE OF CORONAVIRUS INFECTIONS

WO - 11.05.2023

CIP A61K 33/04 № do pedido PCT/IB2022/060575 Requerente SULFAGENIX, INC. Inventor GOJON-ZORRILLA, Gabriel

The present invention features compositions and methods for treating sequelae of coronavirus infection, e.g., betacoronavirus. The present invention features a method of treating or preventing one or more sequelae of a coronavirus infection. The method includes administering to the subject a pharmaceutical composition including elemental alpha sulfur, highly polar components, and a pharmaceutically acceptable excipient in an amount and for a duration sufficient to treat or prevent the one or more sequelae of the coronavirus infection.

6.4173627EISENOXIHYDROXID-NANOPARTIKEL MIT ANTIVIRALER WIRKUNG GEGEN SARS- UND MERS-CORONAVIREN

EP - 03.05.2023

CIP A61K 33/26 № do pedido 21382974 Requerente CONSEJO SUPERIOR INVESTIGACION Inventor BARBER CASTAÑO DOMINGO F

Coronaviridae viruses usually cause mild respiratory disease in humans, nevertheless, a new infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019, resulting in the ongoing 2019-2021 coronavirus pandemic. The present invention discloses the use of coated iron oxyhydroxide nanoparticles (IOHNPs) for use in the treatment and/or prevention of viral infections caused by Coronaviridae, especially those caused by respiratory syndrome-related coronaviruses such as SARS-CoV and SARS-CoV-2 and MERS-CoV. The iron oxyhydroxide nanoparticles are coated with biocompatible molecules and polymers which bind to the nanoparticle core via oxygen (e.g. sorbitol and sucrose). The IOHNPs were found stable, non-cytotoxic in vitro and can efficiently impair virus replication and transcription. Furthermore, the IOHNPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.

7.4186563CORONAVIRUS-TÖTENDES MITTEL

EP - 31.05.2023

CIP A61P 31/02 № do pedido 21846163 Requerente SANKEI CO LTD Inventor GODA HISATAKA

The present disclosure provides a corona virus killing agent. In particular, the present disclosure provides a corona virus killing agent containing chlorous acid water. In particular, the present disclosure provides a method for killing corona virus, using chlorous acid water. The free chlorine concentration of the chlorous acid water (as Cl = 35.45) may be at least 5 ppm or greater in the absence of organic matter. The content of chlorous acid in the chlorous acid water (as HClO₂ = 68.46) may be at least 200 ppm or greater in the presence of organic matter such as when disinfecting hands/fingers. The corona virus may be SARS corona virus (SARS-CoV), MERS corona virus (MERS-CoV), or the 2019 novel corona virus (SARS-CoV-2).

8.4201412PRÄVENTIVE ODER THERAPEUTISCHE PHARMAZEUTISCHE ZUSAMMENSETZUNG FÜR CORONAVIRUS-INFEKTION MIT TETRAARSENISCHEM HEXOXID

EP - 28.06.2023

CIP A61K 33/36 № do pedido 21809186 Requerente CHEMAS CO LTD Inventor BAE ILL JU

Disclosed herein is a pharmaceutical composition comprising tetraarsenic hexoxide as an active ingredient. Having excellent antiviral activity against coronaviruses, the pharmaceutical composition can be advantageously applied to the prevention or treatment of coronavirus diseases.

9.WO/2023/001814COMPOSITION FOR USE IN THE PREVENTION OF SEVERE FORMS OF VIRAL INFECTIONS DUE TO BETACORONAVIRUS

WO - 26.01.2023

CIP A61K 31/155 № do pedido PCT/EP2022/070184 Requerente CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES Inventor CORBEAU, Pierre

The present invention concerns a composition comprising an Angiotensin receptor 1 (AT1) inhibitor and one or more other active compounds selected from the group consisting of antioxidants, caspase inhibitors, and mixtures thereof, for use as a drug in subjects in need thereof, for preventing and/or treating viral infections due to at least one betacoronavirus, in particular for preventing severe forms of viral infections due to betacoronavirus, in particular COVID-19 due to SARS-CoV-2.

10.20230181632PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR CORONAVIRUS INFECTION COMPRISING TETRAARSENIC HEXOXIDE

US - 15.06.2023

CIP A61K 33/36 № do pedido 17926480 Requerente CHEMAS CO., LTD. Inventor Ill Ju BAE

1 / 218

Ir para texto da pesquisa	`CTRL` + `SHIFT` +
Ir para resultados (registo selecionado)	`CTRL` + `SHIFT` +
Ir para detalhes (guia selecionada)	`CTRL` + `SHIFT` +
Ir para página seguinte	`CTRL` +
Ir para página anterior	`CTRL` +

Ir para registo/imagem seguinte	/
Ir para registo/imagem anterior	/
Para cima	`Page Up`
Para baixo	`Page Down`
Para o topo	`CTRL` + `Home`
Para o fundo	`CTRL` + `End`

Em processamento

Entradas na fase nacional

Lista autorizada

Configurações

Comentários

Ir para pedido

Salvar consulta

Árvore da consulta

Redefinir opções

Consulta inteira

Atalhos de visualização lado a lado

Análise